FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial

FibroGen Inc FGEN has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia (CIA).
The trial met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion.
Related: After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat In CKD-Associated Anemia
92 patients with non-myeloid malignancy (solid tumor) having a hemoglobin level at or below 10 g/dL were enrolled in the trial.
Roxadustat was generally well tolerated, and there were no substantive differences in treatment-emergent adverse events (TEAEs) between arms with different starting doses.
The full results of the study will be presented at a medical meeting later this year.
Price Action: FGEN shares are down 0.21% at $12.08 during the market session on the last check Wednesday.

Momentum5.04

GrowthNot Available

QualityNot Available

Value25.82

Short

Medium

Long